| DB ID | MyCo_1007 |
| Title | Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis |
| Year | 2022 |
| PMID | 35251033 |
| Fungal Diseases involved | Invasive Pulmonary Mucormycosis |
| Associated Medical Condition | None |
| Genus | Rhizopus |
| Species | arrhizus |
| Organism | Rhizopus arrhizus |
| Ethical Statement | The animal study was reviewed and approved by MD Anderson Cancer Center Institutional Animal Care and Use Committee. |
| Site of Infection | None |
| Opportunistic invasive | Invasive/Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | IL-6 |
| Biomarker Full Name | Interleukin-6 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Eight-week-old female BALB/cAnNCrl inbred mice (Charles River Laboratories, weight 20 22 g) were immunosuppressed with 3 intraperitoneal injections of cyclophosphamide (Sigma- Aldrich, 150 mg/kg body weight on days -4 and -1, 100 mg/kg on day +3) and a subcutaneous injection of cortisone acetate. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive mucormycosis (IM) is an aggressive and frequently lethal mold infection. Pneumonia is the most common manifestation of IM in patients with severe immunosuppression. As immunological recovery is a major determinant of therapeutic success, facile adjunct immune enhancement strategies are a major unmet need to improve the detrimental outcomes of invasive mold infections. Although cellular immune therapeutics such as adoptive T-cell transfer yielded promising results in-vitro and in animal models of IM, the clinical translation of these approaches is hampered by feasibility concerns (e.g., time-consuming production of cellular products), high cost, and regulatory obstacles. |
| Technique | Assay |
| Analysis Method | 19-plex magnetic Luminex assay (R&D Systems) |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Flow Cytometry Analysis, 19-plex magnetic Luminex assay (R&D Systems) |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
